Dr. Thomas Klaue has been on the advisory board since 2019 and was appointed CEO of SIQENS GmbH in July 2022. His mission: to develop the company into an international provider of hydrogen infrastructure solutions and off-grid power supply solutions for critical environments.
This task was preceded by around 20 years as CFO and CEO in mostly listed companies in the healthcare/life science and technology sectors. These included positions at Injex Pharma GmbH (Medtech), MK-Kliniken AG (Health Care) and Medigene AG (Biotech-Pharma). As Vice President Business Development at Infineon Technologies AG, he was responsible for corporate venture capital and the global biochip business. Before that, he worked as head of the M&A department at DASA (now Airbus) on the realignment of the aerospace industry into today's European structures.
Before Dr. When Klaue moved into industry, he worked in research. First as a university assistant at the University of Mannheim, later as a scholarship holder from the German Research Foundation as a research fellow at M.I.T. Sloan School of Management in Boston. His research focus was 'Innovation Management' and 'Organizational Changes' in industrial companies. He has a degree as Dipl.-Ing. and a Dr. rer. pole. the universities of Karlsruhe and Mannheim. He also completed management training at Harvard Business School.
May 09, 2025Electrochemical Hydrogen Separation as the Key to De-carbonized Economies